Aller au contenu principal
Accès ouvert déclaré 2026 article

Clinical Efficacy and Brain Volumetric Changes in Pediatric-Onset Multiple Sclerosis Under Teriflunomide Treatment

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background Brain volumetric imaging provides important insights into neuroaxonal injury in pediatric-onset multiple sclerosis (POMS), beyond conventional clinical measures of disease activity. Objective To evaluate the longitudinal brain volume changes in POMS patients treated with teriflunomide from disease onset, and to explore their associations with clinical outcomes, including annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS) scores. Methods This retrospective longitudinal study included treatment-naïve POMS patients with standardized 1.5-tesla (T) brain MRIs at baseline and 24-month follow-up. Brain volumes were quantified using fully automated volBrain software. Clinical measures included ARR and EDSS scores. Results Sixteen patients (median age: 15 years; 62.5% female) were included. All patients received teriflunomide as a first-line therapy. Over the 24-month follow-up, the mean ARR decreased from 2.1 to 0.53 and the median EDSS remained stable. Significant reductions were observed in total brain volume ( P = .02), as well as in regional structures including the thalamus ( P = .02), total gray matter ( P = .01), amygdala ( P = .02), and limbic cortex ( P = .004). Conclusions In this real-world cohort of POMS patients treated with teriflunomide, measurable brain volume loss was observed over a 24-month period despite a reduction in relapse activity and stable EDSS scores. These findings provide exploratory evidence of longitudinal volumetric change in a teriflunomide-treated POMS cohort despite residual clinical disease activity. Given the limitations of the study design, including the absence of a control group, these results should be interpreted cautiously and warrant confirmation in larger, controlled longitudinal studies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Clinical Efficacy and Brain Volumetric Changes in Pediatric-Onset Multiple Sclerosis Under Teriflunomide Treatment
Date Crossref
28/07/2026
Éditeur
SAGE Publications
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersAmyotrophic Lateral Sclerosis Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.